Compare BRID & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ANIX |
|---|---|---|
| Founded | 1932 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 103.9M |
| IPO Year | 1995 | 2013 |
| Metric | BRID | ANIX |
|---|---|---|
| Price | $5.26 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 4.2K | ★ 196.1K |
| Earning Date | 08-24-2026 | 09-09-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $5.18 | $2.32 |
| 52 Week High | $8.50 | $5.46 |
| Indicator | BRID | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 36.43 |
| Support Level | N/A | N/A |
| Resistance Level | $5.80 | $3.09 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.42 | 3.72 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.